Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma (Nasdaq: COCP), a clinical-stage biotechnology company, announced it will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference from March 15-17, 2021. The company specializes in developing antiviral therapeutics targeting various viruses, including SARS-CoV-2 and hepatitis C. A pre-recorded webcast of Cocrystal's presentation is available on their website. Interested investors can arrange virtual meetings through Roth Capital Partners or LHA Investor Relations.
Cocrystal Pharma (Nasdaq: COCP) will present an overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The conference will showcase the company's efforts in discovering and developing innovative antiviral therapeutics for various viruses, including influenza and SARS-CoV-2. Access to the webcast presentation is available through registration for the conference, starting from March 9 at 7:00 a.m. Eastern time to March 10 at 9:00 p.m. Eastern time.
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the H.C. Wainwright Global Life Sciences Virtual Conference on January 9-10, 2021, where management will present a company overview and engage in virtual investor meetings. Interested participants can access the presentation by registering for the conference. The webcast will be available from March 9, 2021, at 7:00 a.m. Eastern time to March 10, 2021, at 9:00 p.m. Eastern time. Cocrystal specializes in developing antiviral therapeutics targeting various viruses, including SARS-CoV-2 and influenza.
Cocrystal Pharma (COCP) announced a presentation by President Sam Lee at the virtual 3rd Annual reimagine Health Research Symposium on January 21, 2021. Lee will discuss the company's structure-based drug design technology aimed at developing broad-spectrum antiviral therapies targeting COVID-19, influenza, and hepatitis C. Highlights include the progress of CC-31244, a Phase 2a HCV inhibitor, and CC-42344, an influenza A inhibitor expected to enter Phase 1 trials. The presentation emphasizes the platform's efficiency in drug discovery and its potential to combat high-value diseases.
Cocrystal Pharma (Nasdaq: COCP) has successfully completed its research obligations under its collaboration agreement with Merck within the initial two-year timeline. Merck will now assume full responsibility for the development of influenza A/B antiviral compounds discovered using Cocrystal's advanced technologies. This collaboration, praised for its efficacy, signifies a crucial step in addressing the urgent medical need for new influenza antivirals. Merck's ongoing development efforts will be crucial for these compounds’ future commercialization.
Cocrystal Pharma, Inc. (Nasdaq: COCP), a clinical-stage biotechnology company, announces that President Sam Lee, Ph.D., will present at the 3rd Annual reimagine Health Research Symposium on January 21, 2021. His presentation, titled “Application of structure-based drug design platform technology for developing broad spectrum COVID-19, influenza, and HCV antivirals,” will showcase the company's platform technology in antiviral drug discovery. Cocrystal recently selected a lead compound for its COVID-19 program, advancing its efforts against coronaviruses.
Cocrystal Pharma (Nasdaq: COCP), a clinical-stage biotechnology company, will present at NobleCon17 on January 19, 2021, at 2:15 p.m. ET. This annual investor conference focuses on innovative pharmaceutical developments, specifically novel antiviral therapeutics. The live presentation can be accessed at www.noblecon17.com, with a high-definition video available post-event on Cocrystal's website starting January 20, 2021. Cocrystal specializes in antiviral drugs targeting influenza, hepatitis C, coronaviruses, and noroviruses.
BOTHELL, Wash., Jan. 5, 2021 – Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that management will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be accessible on the company’s website starting January 11, 2021, at 6:00 a.m. Eastern time. CEO Gary Wilcox highlighted the company's progress in advancing its pipeline of novel antiviral compounds during 2020 and expressed anticipation for discussing upcoming milestones at the conference.
For more details about Cocrystal, visit www.cocrystalpharma.com.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has selected CDI-45205 as its lead compound for developing antiviral treatments targeting coronaviruses, including SARS-CoV-2. This compound, acquired under an exclusive licensing agreement from Kansas State University, has shown promise in preclinical studies. Cocrystal plans to initiate API synthesis and IND-enabling studies for CDI-45205, which may be delivered through injection or inhalation. The company also aims to develop additional oral coronavirus inhibitors using its proprietary technology. These efforts are viewed as complementary to existing COVID-19 vaccines.
Cocrystal Pharma (COCP) reported its Q3 2020 results, revealing a revenue of $489,000, slightly down from $492,000 year-over-year. The company closed the quarter with $31.8 million in cash, enabling the expansion of COVID-19 and Influenza A programs. Key developments include positive in vitro data for lead molecule CC-42344 against influenza and ongoing collaborations with Merck for influenza antiviral agents. Net losses increased to $2.67 million, reflecting higher R&D expenses due to COVID-19 initiatives. The company anticipates advancing its IND-enabling studies and initiating Phase 1 trials in 2021.